295 related articles for article (PubMed ID: 20538785)
1. Bevacizumab increases risk for severe proteinuria in cancer patients.
Wu S; Kim C; Baer L; Zhu X
J Am Soc Nephrol; 2010 Aug; 21(8):1381-9. PubMed ID: 20538785
[TBL] [Abstract][Full Text] [Related]
2. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
[TBL] [Abstract][Full Text] [Related]
5. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.
Lafayette RA; McCall B; Li N; Chu L; Werner P; Das A; Glassock R
Am J Nephrol; 2014; 40(1):75-83. PubMed ID: 25059491
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
7. [Bevacizumab and arterial hypertension or proteinuria: management].
Senellart H; Bennouna J
Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832
[TBL] [Abstract][Full Text] [Related]
8. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
Zhu X; Wu S; Dahut WL; Parikh CR
Am J Kidney Dis; 2007 Feb; 49(2):186-93. PubMed ID: 17261421
[TBL] [Abstract][Full Text] [Related]
9. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.
Geiger-Gritsch S; Stollenwerk B; Miksad R; Guba B; Wild C; Siebert U
Oncologist; 2010; 15(11):1179-91. PubMed ID: 21045188
[TBL] [Abstract][Full Text] [Related]
10. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
Hapani S; Sher A; Chu D; Wu S
Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
[TBL] [Abstract][Full Text] [Related]
15. Intricacies of bevacizumab-induced toxicities and their management.
Gressett SM; Shah SR
Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
Hurwitz H; Saini S
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
[TBL] [Abstract][Full Text] [Related]
17. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and tolerability of bevacizumab in children with primary CNS tumors.
Reismüller B; Azizi AA; Peyrl A; Heinrich M; Gruber-Olipitz M; Luckner D; Rothschild KV; Slavc I
Pediatr Blood Cancer; 2010 May; 54(5):681-6. PubMed ID: 20066713
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis.
Kanbayashi Y; Ishikawa T; Tabuchi Y; Sakaguchi K; Ouchi Y; Otsuji E; Takayama K; Taguchi T
Sci Rep; 2020 Feb; 10(1):2011. PubMed ID: 32029849
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
Cao Y; Tan A; Gao F; Liu L; Liao C; Mo Z
Int J Colorectal Dis; 2009 Jun; 24(6):677-85. PubMed ID: 19184059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
